REGENXBIO Inc. (RGNX)
- Previous Close
9.35 - Open
9.50 - Bid --
- Ask --
- Day's Range
9.26 - 9.74 - 52 Week Range
9.11 - 28.80 - Volume
437,604 - Avg. Volume
495,510 - Market Cap (intraday)
481.382M - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
-- - EPS (TTM)
-5.26 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
36.54
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
www.regenxbio.comRecent News: RGNX
View More
Performance Overview: RGNX
Trailing total returns as of 10/28/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGNX
View MoreValuation Measures
Market Cap
462.11M
Enterprise Value
257.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.84
Price/Book (mrq)
1.33
Enterprise Value/Revenue
2.89
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-270.74%
Return on Assets (ttm)
-24.26%
Return on Equity (ttm)
-63.94%
Revenue (ttm)
89.04M
Net Income Avi to Common (ttm)
-241.08M
Diluted EPS (ttm)
-5.26
Balance Sheet and Cash Flow
Total Cash (mrq)
290.36M
Total Debt/Equity (mrq)
45.57%
Levered Free Cash Flow (ttm)
-105.63M
Research Analysis: RGNX
View MoreCompany Insights: RGNX
RGNX does not have Company Insights
Research Reports: RGNX
View MoreLowering target price to $10.00
REGENXBIO INC has an Investment Rating of HOLD; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $11.00
REGENXBIO INC has an Investment Rating of HOLD; a target price of $11.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRating increased to a HOLD
REGENXBIO INC has an Investment Rating of HOLD; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRating decreased to a SELL
REGENXBIO INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target